IPH5301

News alerts, weekly reports and conference planners

Company:

Innate

Drug class:

CD73 inhibitor

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

4 days ago

Trial completion date • Trial primary completion date • First-in-human

PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)

PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression

Herceptin (trastuzumab) • paclitaxel • IPH5301

2ms

Design, engineering, and functional evaluation of nanobody-based anti-CD73 for immunogenic cell death induction in chemoresistant colorectal Cancer cell line. (PubMed, Int Immunopharmacol)

HeLiNa-73 combines CD73 inhibition with ICD induction, thereby overcoming adenosine-mediated immune suppression while enhancing tumor immunogenicity. These in vitro findings highlight HeLiNa-73 as a next-generation nanobody-based candidate for in vivo chemoresistant CRC studies and to synergize with checkpoint blockade.

2 months ago

Preclinical • Journal

HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)

IPH5301

2years

CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Mar 2024 --> Mar 2025

2 years ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

HER-2 positive • HER-2 overexpression

Herceptin (trastuzumab) • paclitaxel • IPH5301